Frequently Asked Questions

About Vicus.  Vicus Therapeutics, Morristown, NJ, is a biopharmaceutical company dedicated to bringing breakthrough adjunct therapies to patients with cancer. Vicus’ lead investigational therapy, VT-122, is a combination of etodolac and propranolol. VT-122 showed positive results in a Phase 2 clinical trial of lung cancer patients and is currently being evaluated in a Phase 2 clinical trial of liver cancer patients receiving Nexavar (sorafenib).

Vicus business is making Pharma's anti-cancer drugs more valuable.  Vicus partners with pharmaceutical company oncology units’ management teams to develop and enable adoption of co-administered repurposed drugs that increase efficacy, tolerability and duration of therapy of their anti-cancer drugs’ on-label indications.

Who we work with. Vicus works with its Pharma partner's oncology units’ general managers and vice presidents of marketing, medical affairs and business development. In addition, Vicus works with leading physicians, whom are members of the most recognized physician practice guideline groups, to design, execute and interpret clinical studies of its repurposed drugs.

What we do.  Vicus identifies and patents novel uses of off-patent drugs that are approved for non-cancer indications and have shown efficacy in cancer. Vicus generates clinical data on the use of the repurposed drugs with anti-cancer drugs for evaluation by the FDA, European Medicines Agency, PMDA and other regulatory agencies.  Investigators publish the clinical data for evaluation by panel members of the physician practice guideline groups. The panel members interpret the data to develop Clinical Practice Guidelines for the co-administration of anti-cancer and repurposed drugs.

How we do it.  Using its proprietary systems biology model of cancer and its treatment, Vicus screens published data to identify repurposed drug candidates, secures US FDA INDs using the 505(b)(2) regulatory pathway, conducts add-on clinical studies of its repurposed drugs with Pharma partners' anti-cancer drugs and seeks US FDA New Drug Approvals of its repurposed drugs upon completion of clinical studies.